Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Sopherion completes $47mm Series B

02 Nov 2004

Executive Summary

Start-up cancer treatment developer Sopherion Therapeutics has completed a $47mm Series B round led by returning investor TL Ventures. Other first round backers ProQuest, HealthCap, and Seaflower Ventures, and new investors Sprout Group (invested $12mm), Canaan Partners, NewSpring Ventures LP, and Commerce Health Ventures (a fund of NewSpring) also participated.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By